Search Results

Displaying Results 1-1 of 1 "'BCRX'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Jan 07, 2026, 17:12 ET Astria Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Astria Therapeutics, Inc. (NasdaqGM: ATXS) to BioCryst Pharmaceuticals, Inc. (NasdaqGS: BCRX). Under the terms of the proposed transaction, shareholders of Astria will receive $8.55 in cash and 0.59 shares of BioCryst common stock for each share

More news about: Kahn Swick & Foti, LLC

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.